Heron Therapeutics’ (HRTX) “Buy” Rating Reiterated at Jefferies Group LLC
Heron Therapeutics, Inc. (NASDAQ:HRTX)‘s stock had its “buy” rating reiterated by stock analysts at Jefferies Group LLC in a report released on Wednesday. Jefferies Group also issued estimates for Heron Therapeutics’ Q3 2017 earnings at ($0.89) EPS, Q4 2017 earnings at ($0.96) EPS, FY2017 earnings at ($3.52) EPS, FY2018 earnings at ($2.28) EPS and FY2019 earnings at ($1.00) EPS.
Other equities research analysts have also issued reports about the stock. Cantor Fitzgerald reissued a “buy” rating and issued a $31.00 target price (up from $30.00) on shares of Heron Therapeutics in a report on Thursday, May 11th. ValuEngine raised shares of Heron Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. Cowen and Company reaffirmed a “buy” rating and set a $40.00 price objective on shares of Heron Therapeutics in a report on Friday, May 26th. Aegis reaffirmed a “buy” rating and set a $33.00 price objective on shares of Heron Therapeutics in a report on Tuesday, July 18th. Finally, Noble Financial reaffirmed a “buy” rating on shares of Heron Therapeutics in a report on Thursday, August 10th. Two analysts have rated the stock with a sell rating and eleven have assigned a buy rating to the company. Heron Therapeutics has a consensus rating of “Buy” and a consensus target price of $31.00.
Shares of Heron Therapeutics (NASDAQ HRTX) remained flat at $15.25 during trading on Wednesday. 398,607 shares of the company were exchanged. The stock has a 50 day moving average of $15.54 and a 200-day moving average of $14.67. Heron Therapeutics has a 12 month low of $12.21 and a 12 month high of $21.24.
Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.90) by $0.10. The firm had revenue of $8.51 million during the quarter, compared to analysts’ expectations of $4.53 million. On average, equities analysts expect that Heron Therapeutics will post ($3.50) EPS for the current fiscal year.
Large investors have recently made changes to their positions in the stock. Janus Henderson Group PLC purchased a new position in Heron Therapeutics during the second quarter worth approximately $78,134,000. Tang Capital Management LLC increased its position in Heron Therapeutics by 39.7% in the first quarter. Tang Capital Management LLC now owns 8,654,914 shares of the biotechnology company’s stock worth $129,824,000 after buying an additional 2,457,716 shares in the last quarter. FMR LLC increased its position in Heron Therapeutics by 36.7% in the first quarter. FMR LLC now owns 8,030,880 shares of the biotechnology company’s stock worth $120,464,000 after buying an additional 2,158,041 shares in the last quarter. Citadel Advisors LLC increased its position in Heron Therapeutics by 529.5% in the first quarter. Citadel Advisors LLC now owns 1,283,679 shares of the biotechnology company’s stock worth $19,255,000 after buying an additional 1,079,746 shares in the last quarter. Finally, Rubric Capital Management LP increased its position in Heron Therapeutics by 190.9% in the first quarter. Rubric Capital Management LP now owns 1,600,000 shares of the biotechnology company’s stock worth $24,000,000 after buying an additional 1,050,000 shares in the last quarter.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.